{"protocolSection":{"identificationModule":{"nctId":"NCT07020923","orgStudyIdInfo":{"id":"VT-001-0020"},"organization":{"fullName":"Vera Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Monthly Dosing of Atacicept in IgAN","officialTitle":"A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN"},"statusModule":{"statusVerifiedDate":"2025-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-05-13","studyFirstSubmitQcDate":"2025-06-05","studyFirstPostDateStruct":{"date":"2025-06-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-06-17","lastUpdatePostDateStruct":{"date":"2025-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vera Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept","detailedDescription":"This Phase 2 study is to explore the effectiveness, safety and tolerability of different dosing regimens of atacicept. Regimens include monthly and weekly dosing."},"conditionsModule":{"conditions":["IgA Nephropathy (IgAN)","Berger Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":90,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Atacicept Arm 1","type":"EXPERIMENTAL","description":"Atacicept dose A administered subcutaneous (sc) injection monthly","interventionNames":["Drug: Atacicept"]},{"label":"Atacicept Arm 2","type":"EXPERIMENTAL","description":"Atacicept dose B administered subcutaneous (sc) injection monthly"},{"label":"Atacicept Arm 3","type":"EXPERIMENTAL","description":"Atacicept dose C administered subcutaneous (sc) injection monthly"},{"label":"Atacicept Arm 4","type":"EXPERIMENTAL","description":"Atacicept dose D administered subcutaneous (sc) injection weekly"},{"label":"Atacicept Arm 5","type":"EXPERIMENTAL","description":"Atacicept dose E administered subcutaneous (sc) injection weekly for 24 weeks, followed by monthly sc injections"}],"interventions":[{"type":"DRUG","name":"Atacicept","description":"Drug: Atacicept","armGroupLabels":["Atacicept Arm 1"],"otherNames":["VT-001"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN","description":"Gd-IgA1 levels through Week 24","timeFrame":"Up to 24 weeks"}],"secondaryOutcomes":[{"measure":"To evaluate the safety and tolerability of atacicept at different dosing regimensT","description":"Incidence of treatment emergent reported Adverse Events (AE)","timeFrame":"Baseline until end of study up to Week 24"},{"measure":"To evaluate the effect of atacicept on serum immunoglobulins (IgA)","description":"IgA levels through Week 24","timeFrame":"24 Weeks"},{"measure":"To evaluate the effect of atacicept on serum immunoglobulins (IgG)","description":"IgG levels through Week 24","timeFrame":"24 Weeks"},{"measure":"To evaluate the effect of atacicept on serum immunoglobulins (IgM)","description":"IgM levels through Week 24","timeFrame":"24 Weeks"},{"measure":"To evaluate serum PK of atacicept","description":"Serum concentration of atacicept","timeFrame":"Baseline until end of study up to Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study assessments\n* Adult male or female of ≥18 years of age, or as per country specific legally or nationally recognized adult age, who provides written informed consent prior to performing any study assessments\n* Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years\n* Total urine protein excretion ≥0.75 g per 24-hour or urine protein-to-creatinine ratio (UPCR) ≥0.75 mg/mg based on a 24-hour urine sample\n* eGFR ≥30 mL/min/1.73 m2 at screening, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)\n* On a stable prescribed regimen of RASi (angiotensin converting enzyme inhibitor or angiotensin II receptor blocker) for at least 8 weeks that is at the maximum labeled or tolerated dose at screening and from screening to study Day 1\n\nExclusion Criteria:\n\n* IgAN secondary to another condition (eg, liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (ie, Henoch-Schonlein purpura), systemic lupus erythematosus, dermatitis herpetiformis, ankylosing spondylitis\n* Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months of screening)\n* Evidence of nephrotic syndrome within 6 months of screening (serum albumin \\<3.0 g/dL in association with UPCR \\>3.5 mg/mg)\n* Renal or other organ transplantation prior to or expected during the study, with the exception of corneal transplants\n* Concomitant chronic renal disease in addition to IgAN (eg, diabetic nephropathy, primary focal segmental glomerulosclerosis, membranous nephropathy, C3 glomerulopathy, lupus nephritis)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Vera Therapeutics, Inc. Clinical Trials Information","role":"CONTACT","phone":"(650)770-0077","email":"clinicaltrials@veratx.com"}],"overallOfficials":[{"name":"Zeeshan Khawaja","affiliation":"Vice President, Clinical Development","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Vera Therapeutics","status":"RECRUITING","city":"Brisbane","state":"California","zip":"94005","country":"United States","contacts":[{"name":"Brisbane, California","role":"CONTACT","phone":"(650) 770-0077","email":"clinicaltrials@veratx.com"}],"geoPoint":{"lat":37.68077,"lon":-122.39997}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Vera Therapeutics, Inc Company Website","url":"http://www.veratx.com"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D005922","term":"Glomerulonephritis, IGA"}],"ancestors":[{"id":"D005921","term":"Glomerulonephritis"},{"id":"D009393","term":"Nephritis"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C524618","term":"TACI receptor-IgG Fc fragment fusion protein"}]}},"hasResults":false}